Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.
about
Epigenetic contributions in the development of rheumatoid arthritisPreclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.Strategies for controlled delivery of biologics for cartilage repair.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerAntitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model.Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritisHistone Deacetylases in Bone Development and Skeletal Disorders.Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in miceHistone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretionEpigenetic targets for reversing immune defects caused by alcohol exposure.HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.HDACi: molecular mechanisms and therapeutic implications in the innate immune system.Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.Epigenetics in rheumatoid arthritis: a primer for rheumatologists.Glucocorticoid sensitivity in health and disease.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenetics and Bone Remodeling.Epigenetic drug discovery: breaking through the immune barrier.The acetyl code in rheumatoid arthritis and other rheumatic diseases.Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes.Histone deacetylase inhibitor vorinostat (SAHA, MK0683) perturb miR-9-MCPIP1 axis to block IL-1β-induced IL-6 expression in human OA chondrocytes.Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1β-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis ChondrocyteHistone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1β and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model.Epigenetics of inflammatory arthritis.Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.Immunopathogenesis of Rheumatoid Arthritis.The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy
P2860
Q26849371-67FB949B-DB36-4EBE-AADD-4BDF3821D08CQ33654202-EAFEE5C6-09EC-43BC-8F56-5CC4549D812BQ33869272-52DF4290-036B-45AC-BEDD-7FC275E87E80Q34356521-FA1AFD67-19D2-4C13-8861-7A6EE500A8BEQ34791411-4707A564-8478-4531-AE06-D573C0AE8571Q35016934-63CAF5E6-244D-4E12-A264-35E4657D87B1Q35058878-29CF756E-9B1B-47F7-A6E1-7A293FA2FC8DQ36095497-29B7C143-9640-4D5C-9FF8-51B484C81419Q36146330-3069EB15-B622-4280-8CF9-ACEFC57591ABQ36351364-08968EC3-B401-4577-9DF0-2B882ABD9F32Q36742145-FB1F4F3E-50AE-473C-BD49-8DD6E5647D43Q37386440-007E1953-64BE-41BB-869D-E4476FA8B279Q37838731-981AE368-3A34-4BBD-BDC9-AD3B1B9C7F89Q37956176-33023EF5-6CBE-4657-9F4D-5AC9EF383A2EQ38008692-A0F5030E-BE03-4734-AD45-DD6FF4DB9241Q38145001-31711D67-5202-4C23-A3DC-3071D4687423Q38147870-FADC8AA4-854E-4D5C-ACC1-478BC4663512Q38240733-C0FDEBE9-7F09-4EA8-A634-19AF40E618DBQ38624611-E2978ED0-596F-4A55-876F-9B9C13CCB502Q38986705-FDAEAA76-9805-4C68-8172-69FD51B73873Q39094945-949592B6-2357-45F8-BF8D-059015E9118DQ39168362-0A101771-B546-42A0-860E-482F0A6829EEQ39189613-4F61396D-B0E9-48B7-A38E-6299852FBE83Q39609958-9C7E1AF5-AE81-41E2-8CB8-F5C96FBE5B8FQ41042385-B4BFB982-FB56-4E39-A907-AA71A01DC961Q41544554-42038704-FCF7-473C-BF9E-8E556535B162Q41630267-EE3A3525-B0E7-490D-843C-074BCB5BFFFBQ42815246-2E7F7D09-A32B-4ABD-A8BA-10312A3EFC58Q45967099-23D9F089-E93A-4046-AFCF-E28F635D76D8Q50067303-C7F03F0F-3270-4710-AEA1-DC5B36887883Q53662447-EBBE0C05-3EFA-40B7-AFC0-931FAEDB31ECQ54161049-5D6F420C-6D79-461F-BEA3-B63180AD386AQ54430437-798CFA93-0FAB-4449-8B2F-7E4BA7FA20E4Q59125138-A9607421-4AD2-4108-A9AE-B4D055DCC066
P2860
Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@en
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@nl
type
label
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@en
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@nl
prefLabel
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@en
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@nl
P2093
P2860
P1433
P1476
Inhibition of HDAC activity by ...... ion in experimental arthritis.
@en
P2093
Flavio Leoni
Leo A B Joosten
Paolo Mascagni
Sajeda Meghji
P2860
P2888
P304
P356
10.2119/MOLMED.2011.00058
P407
P577
2011-02-11T00:00:00Z
P5875
P6179
1068965376